Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor

Journal of Molecular Medicine

Volumn 92, Issue 1, 2014, Pages 65-76

  Vigna, Elisa ^a,b   Pacchiana, Giovanni ^a,b   Chiriaco, Cristina ^a   Cignetto, Simona ^a,b   Fontani, Lara ^a   Michieli, Paolo ^a,b   Comoglio, Paolo M ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Antibody; Cancer; Gene therapy; Lentiviral vector; Met; Targeted therapy

Indexed keywords

DOXYCYCLINE; IMMUNOGLOBULIN F(AB) FRAGMENT; LENTIVIRUS VECTOR; RECEPTOR ANTIBODY; SCATTER FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TRANSFER; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHENOTYPE; TRANSGENE; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LENTIVIRUS; LUNG NEOPLASMS; MICE; PROTO-ONCOGENE PROTEINS C-MET; TRANSDUCTION, GENETIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891884307     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1079-0     Document Type: Article

References (34)

1. Martini M, Secchione L, Siena S, Tejpar S, Bardelli A (2011) Targeted therapies: how personal should we go? Nat Rev Clin Oncol 9:87-97
2. De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P et al (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72:4537-4550
3. Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 7:401-414
4. Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493-507
5. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043 (Pubitemid 46799492)
6. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-20937
7. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89-103
8. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM (1998) Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 111:237-247 (Pubitemid 28064148)
9. Vigna E, Pacchiana G, Mazzone M, Chiriaco C, Fontani L, Basilico C, Pennacchietti S, Comoglio PM (2008) "Active" cancer immunotherapy by anti-Met antibody gene transfer. Cancer Res 68:9176-9183
10. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, Comoglio PM, Giordano S (2006) Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci U S A 103:5090-5095
11. Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, Giordano S, Fafeur V, Tulasne D (2009) Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 20:2495-2507
12. Schelter F, Kobuch J, Moss ML, Becherer JD, Comoglio PM, Boccaccio C, Kruger A (2010) A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem 285:26335-26340
13. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, Comoglio PM (2004) Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6:61-73 (Pubitemid 38903162)
14. Pacchiana G, Chiriaco C, Stella MC, Petronzelli F, De Santis R, Galluzzo M, Carminati P, Comoglio PM, Michieli P, Vigna E (2010) Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. J Biol Chem 285:36149-36157
15. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci U S A 97:7963-7968 (Pubitemid 30460756)
16. Vigna E, Cavalieri S, Ailles L, Geuna M, Loew R, Bujard H, Naldini L (2002) Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 5:252-261 (Pubitemid 34211220)
17. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217-222 (Pubitemid 30394997)
18. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67:2081-2088 (Pubitemid 46424226)
19. Bertotti A, Burbridge MF, Gastaldi S, Salimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP et al (2009) Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2:er11
20. Chattopadhyay N, Butters RR, Brown EM (2001) Agonists of the retinoic acid- and retinoid X-receptors inhibit hepatocyte growth factor secretion and expression in U87 human astrocytoma cells. Brain Res Mol Brain Res 87:100-108 (Pubitemid 32167045)
21. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K (2006) A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144-6152 (Pubitemid 44703780)
22. Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S et al (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 66:1721-1729 (Pubitemid 43259957)
23. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408-4417 (Pubitemid 46815090)
24. Follenzi A, Sabatino G, Lombardo A, Boccaccio C, Naldini L (2002) Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 13:243-260 (Pubitemid 34164109)
25. Gillet JP, Macadangdang B, Fathke RL, Gottesman MM, Kimchi-Sarfaty C (2009) The development of gene therapy: from monogenic recessive disorders to complex diseases such as cancer. Methods Mol Biol 542:5-54
26. Kaneda Y (2010) Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv 7:1079-1093
27. Warnock JN, Daigre C, Al-Rubeai M (2011) Introduction to viral vectors. Methods Mol Biol 737:1-25
28. Vigna E, Naldini L (2000) Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2:308-316
29. Montini E, Cesana D, Schmidt M, Sancito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C et al (2006) Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24:687-696 (Pubitemid 43882120)
30. Mátrai J, Chuah MK, VandenDriessche T (2010) Recent advances in lentiviral vector development and applications. Mol Ther 18:477-490
31. De Palma M, Mazzieri R, Politi LS, Pucci F, Zonari E, Sitia G, Mazzoleni S, Moi D, Venneri MA, Indraccolo S et al (2008) Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14:299-311
32. Sanz L, Compte M, Guijarro-Muñoz I, Álvarez-Vallina L (2012) Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Ther 19:1-7
33. Lal B, Xia S, Abounader R, Laterra J (2005) Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res 11:4479-4486 (Pubitemid 40825638)
34. De Bacco F, Luraghi P, Medico E, Reato G, Girolami F, Perera T, Gabriele P, Comoglio PM, Boccaccio C (2011) Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 103:645-661